🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

BRIEF-Orexigen announces commercialization and distributorship deal with Valeant for Mysimba

Published 2016-03-15, 07:57 a/m
© Reuters.  BRIEF-Orexigen announces commercialization and distributorship deal with Valeant for Mysimba
BHC
-

March 15 (Reuters) - Orexigen Therapeutics Inc:
* Orexigen will retain regulatory affairs responsibilities
in EU countries
* Orexigen will supply Mysimba tablets to Valeant at an
agreed transfer price
* Orexigen Therapeutics announces commercialization and
distributorship agreement with Valeant Pharmaceuticals (NYSE:VRX) for
Mysimba (naltrexone hcl / bupropion hcl prolonged release) for
18 central and eastern european countries and Turkey
* Under terms of agreement, Valeant will be responsible for
commercialization activities in 19 countries
* Under terms of agreement, Valeant will be responsible for
obtaining regulatory approvals in non-EU countries
* Orexigen Therapeutics Inc says announced strategic
acquisition of all U.S. rights to Contrave
* Orexigen Therapeutics Inc says upon completion of
acquisition, Orexigen will own all rights to Contrave in nearly
all global territories

Source text for Eikon: ID:nPnc4vC4da
Further company coverage: OREX.O

(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.